Biogen Idec and Sobi Present New Data from the Phase 3 Study of their Long-Lasting Haemophilia Factor Candidate ELOCTATE(TM)
(Thomson Reuters ONE) -
Additional Analyses from Phase 3 A-LONG Study Support Positive Clinical Profile
of ELOCTATE for Haemophilia A
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:
SOBI) presented new data that support the clinical and safety profile of their
long-lasting recombinant factor VIII candidate ELOCTATE* for haemophilia A. Five
platform and oral presentations at the XXIV International Society on Thrombosis
and Haemostasis (ISTH) Congress in Amsterdam, The Netherlands, highlight the new
FVIII candidate's potential to reduce the number of intravenous injections
people with haemophilia A require, its efficacy in controlling bleeding during
and after surgery, and its efficacy in treating acute bleeding episodes.
"We are excited to share these new data, which include patients' and physicians'
assessment of ELOCTATE's efficacy in treating bleeding episodes and in
controlling bleeding during surgery," said Glenn Pierce, M.D., Ph.D., senior
vice president of Global Medical Affairs and chief medical officer of Biogen
Idec's haemophilia therapeutic area. "The A-LONG data presented at ISTH support
the potential of ELOCTATE to enable longer intervals between prophylactic
(preventative) injections compared to the current standard of care."
Treatment of Bleeding
An evaluation of the treatment of acute bleeding episodes across the prophylaxis
and episodic (on demand) treatment arms of the phase 3 A-LONG study showed that
more than 87% of bleeds were controlled with a single injection of ELOCTATE and
more than 97% of were controlled with two or fewer injections. These data were
showcased in the e-Poster presentation:
* Treatment of Bleeding Episodes in Subjects with Haemophilia A With Long-
Lasting Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Phase 3
A-Long Study
Novel Assay Clinical Research
For the first time Biogen Idec shared results of evaluations of the performance
of ELOCTATE when evaluated using two investigational haemostasis assays.
Results from a large scale, global clinical evaluation of ELOCTATE by thrombin
generation assay (TGA), using a standardized sample collection procedure and an
optimized and validated assay performed at a central laboratory showed that,
despite inherent patient-to-patient differences in thrombin generation activity,
ELOCTATE and Advate** showed equivalent thrombin generation potential post-
infusion. ELOCTATE also showed prolonged thrombin generation activity relative
to Advate, correlating with the pharmacokinetic data observed in these subjects.
Results from a rotation thromboelastometry (ROTEM®) analysis conducted on 44
patients treated with ELOCTATE from 13 A-LONG study sites showed that ELOCTATE
was fully active in patient samples. Additionally, the FVIII activity as
measured by clotting time seen for ELOCTATE at 72 hours after dosing was
comparable to the activity of Advate at 48 hours after dosing (mean clotting
times of 1,238 seconds and 1,213 seconds, respectively).
The data presentations were consistent with conventional assay results from the
A-LONG study. These data were showcased in two oral platform presentations:
* Evaluation of The Thrombin Generation Potential of a Recombinant Factor VIII
Fc Fusion Protein in a Phase III Multi-National Clinical Trial
* Evaluation of Whole Blood Clotting Activity of Recombinant Factor VIII Fc
Fusion Protein by ROTEM Analysis in a Multi-Center Phase 3 Clinical Trial
Surgery Analysis
Results from an analysis of the phase 3 A-LONG study showed that ELOCTATE
consistently controlled bleeding during and after 9 major surgeries in 9
patients with haemophilia A. Physicians reported high efficacy levels of
ELOCTATE during surgery, with haemostasis (the stoppage of bleeding) rated as
"excellent" for 8/9 surgeries and "good" for 1/9 surgeries. According to the
investigators' analysis, the results were comparable to that for similar
surgeries in people without haemophilia. These data were showcased in the e-
poster presentation:
* Long-Lasting Recombinant Factor VIII Fc Fusion (rFVIIIFc) for Perioperative
Management of Subjects with Haemophilia A in the Phase 3 A-LONG Study
Population Pharmacokinetics (PK) Analysis
Analysis of a population pharmacokinetics (popPK) model developed for ELOCTATE
demonstrate that the model accurately predicts peak and trough factor VIII
activity levels achieved in the A-LONG clinical study at a variety of ELOCTATE
doses. These data were showcased in the e-poster presentation:
* Population Pharmacokinetic Analysis of Long-Lasting Recombinant Factor VIII
Fc Fusion Protein (rFVIIIFc) in Patients with Severe Haemophilia A
"These new data from the A-LONG study show potential for the application of Fc
fusion technology in haemophilia," said Birgitte Volck, M.D., Ph.D., senior vice
president development and chief medical officer of Sobi. "We are excited to
share these data on ELOCTATE, which provide additional evidence of the potential
of ELOCTATE to make a meaningful difference in the lives of patients with
haemophilia A."
ELOCTATE Global Regulatory Status
A Biologics License Application (BLA) for Biogen Idec's long-lasting haemophilia
product candidate ELOCTATE is currently under review with the FDA for the
treatment of haemophilia A. If approved, ELOCTATE would be the first major
treatment advance for the haemophilia A community in more than two decades.
A Marketing Application for ELOCTATE has been submitted in Australia for the
treatment of haemophilia A. Additional regulatory filings are planned.
---
About the Fc Fusion Technology Platform
ELOCTATE is a clotting factor under development using Biogen Idec's novel and
proprietary monomeric Fc fusion technology, which makes use of a naturally
occurring pathway that delays the breakdown of factor in the body and cycles it
back into the bloodstream, resulting in a longer circulating half-life. Fc
fusion technology is used in seven FDA-approved products for the treatment of
chronic diseases including rheumatoid arthritis, psoriasis and platelet
disorders. Biogen Idec is the first and only to apply this proprietary
technology to haemophilia.
About Haemophilia A
Haemophilia A is a rare, inherited disorder in which the ability of a person's
blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male
births annually and is caused by having substantially reduced or no factor VIII
activity, which is needed for normal blood clotting. People with haemophilia A
experience bleeding episodes that can cause pain, irreversible joint damage and
life-threatening haemorrhage. Injections of factor VIII can restore the
coagulation process, control bleeding, and prevent new bleeding episodes. The
Medical and Scientific Advisory Council of the National Haemophilia Foundation
recommends prophylaxis as the optimal therapy for people with severe haemophilia
A. Currently, prophylaxis in haemophilia A typically requires injections three
times per week or every other day to maintain a sufficient circulating level of
clotting factor.
About the Biogen Idec and Sobi Collaboration
Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the development
and commercialization of ELOCTATE in haemophilia A and ALPROLIX in haemophilia
B. Biogen Idec leads development, has manufacturing rights, and has
commercialization rights in North America and all other regions excluding the
Sobi territory. Sobi has the right to opt in to assume final development and
commercialization in Europe (including Russia), the Middle East and Northern
Africa.
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(? 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, haemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world's oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than $5 billion in annual revenues. For product
labelling, press releases and additional information about the company, please
visit www.biogenidec.com.
Safe Harbour
This press release contains forward-looking statements, including statements
about the potential impact and therapeutic effect of our long-lasting
haemophilia product candidates and regulatory filings. These statements may be
identified by words such as "believe," "expect," "may," "plan," "potential,"
"will" and similar expressions, and are based on our current beliefs and
expectations. Drug development and commercialization involve a high degree of
risk. Factors which could cause actual results to differ materially from our
current expectations include the risk that unexpected concerns may arise from
additional data or analysis, regulatory authorities may require additional
information or further studies, or may fail to approve or may delay approval of
our drug candidates, or we may encounter other unexpected hurdles. For more
detailed information on the risks and uncertainties associated with our drug
development and commercialization activities, please review the Risk Factors
section of our most recent annual or quarterly report filed with the Securities
and Exchange Commission. Any forward-looking statements speak only as of the
date of this press release and we assume no obligation to update any forward-
looking statements, whether as a result of new information, future events or
otherwise.
*ELOCTATE(TM) Antihaemophilic Factor (Recombinant Fc Fusion Protein)
**Advate® [antihaemophilic factor (recombinant), plasma/albumin-free method] is
a registered trademark of Baxter International Inc.
For more information - not for publication
Sobi
Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819 or +1 212-579-0506
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Biogen Idec
Media Contact Investor Relations Contact
Todd Cooper Ben Strain
Senior Director, Public Affairs Senior Manager, Investor Relations
+1-781-464-3260 +1-781-464-2442
Biogen Idec and Sobi Present New Data from the Phase 3 Study:
http://hugin.info/134557/R/1714266/569207.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1714266]
Unternehmensinformation / Kurzprofil:
Datum: 04.07.2013 - 13:55 Uhr
Sprache: Deutsch
News-ID 275725
Anzahl Zeichen: 13044
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biogen Idec and Sobi Present New Data from the Phase 3 Study of their Long-Lasting Haemophilia Factor Candidate ELOCTATE(TM)"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
